This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Ophthalmic disease				
Glaucoma; ocular hypertension	LIM domain kinase 2 (LIMK2)	<p><i>In vitro</i> and mouse studies identified inhibitors of LIMK2 that could help treat ocular hypertension. In both enzymatic and cellular assays, a class of pyrrolopyrimidine compounds selectively inhibited LIMK2. In a mouse model of steroid-induced ocular hypertension, the LIMK2 inhibitors decreased intraocular pressure to levels comparable to those in healthy controls. Lexicon Pharmaceuticals Inc. is studying the most advanced LIMK2 inhibitor in animal models of glaucoma.</p> <p>SciBX 2(42); doi:10.1038/scibx.2009.1579 Published online Oct. 29, 2009</p>	Patent applications pending worldwide for the LIMK2 inhibitors; Lexicon owns the IP; Lexicon's LIMK2 inhibitor program available for licensing and potential partnerships	<p>Harrison, B. <i>et al. J. Med. Chem.</i>; published online Oct. 15, 2009; doi:10.1021/jm901226j</p> <p>Contact: David B. Rawlins, Lexicon Pharmaceuticals Inc., The Woodlands, Texas</p> <p>e-mail: drawlins@lexpharma.com or bharrison@lexpharma.com</p>